![]() |
NEW YORK, Oct. 17, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.
NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension jwplayer(‘myplayer1’).setup(file: ‘https://mma.prnasia.com/media2/2799213/NYSE_Market_Update_Oct_17.mp4’, image: ‘https://mma.prnasia.com/media2/2799213/NYSE_Market_Update_Oct_17.mp4?p=thumbnail’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’);
Kristen Scholer delivers the pre-market update on October 17th
- Stocks are lower early Friday after regional bank reports created concerns over bad loans. Loose lending practices pushed traders into safe havens. Activity in the banking sector could inform the Fed’s next decision on interest rates.
- Tariff relief is expected for the auto industry after a lobbying push according to reports. The Commerce Department will announce a five-year extension for an agreement that allows carmakers to reduce what they pay in tariffs on car imports.
- Koom 2025 kicked off yesterday in Brooklyn. The three-day conference celebrates Korean start-up culture, innovation, and K-Pop. Korean business leaders will be in attendance.
Opening Bell
The Breast Cancer Research Foundation highlights its mission to end breast cancer by advancing the world’s most promising research
Closing Bell
National Fallen Firefighters Foundation honors and remembers 176 Fallen Firefighters
Click here to download the NYSE TV App
Video – https://mma.prnasia.com/media2/2799213/NYSE_Market_Update_Oct_17.mp4
ข่าวที่เกี่ยวข้อง
- Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
- Innovative Immunology Biotech Windward Bio Lists on Nasdaq
- The NYSE Welcomes vVARDIS as a Publicly Listed Company
- Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
